BUZZ - FIS shares plunge due to falling profits and bleak growth outlook; announces CFO departure
路透社2026/11/04 13:18November 4 - ** Fidelity National Information Services (FIS.N) shares dropped about 19% pre-market to $31.74
** The banking and payment processing company lowered its profit and organic growth expectations for this fiscal year and suspended share buybacks to reduce debt
** Expects adjusted earnings per share for fiscal year 2026 to be $5.82–$5.89, implying growth of 1.2%–2.4%, compared with previous projected growth of 7%–8.5%
** Revised fiscal year organic revenue growth expectations down from 4.5%–5.0% to 3.1%–3.6%
** Revised fiscal year organic adjusted EBITDA growth projections down from 5.9%–6.9% to 2.9%–3.6%
** Chief Financial Officer James Kehoe will step down on November 5
** Third-quarter adjusted earnings per share was $1.61, slightly above analysts' expectation of $1.60—data compiled by LSEG
** Third-quarter revenue was $3.45 billion, just above the expected $3.43 billion; organic revenue grew by 3.7%
** As of the close of the previous trading day, the stock had fallen 41% year-to-date
(To assist non-native English speakers, Reuters has automatically translated its reports into various other languages. Because automated translation may contain errors or miss required context, Reuters does not guarantee the accuracy of the automated translation text and provides it solely for the convenience of readers. Reuters assumes no responsibility for any damage or loss arising from the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading
CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.

AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response
According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.
Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test
Goldman Sachs (GS.US) and Apollo Global Management (APO.US) are in talks with Wall Street investors to begin selling portions of a roughly $40 billion chip financing deal for SpaceX (SPCX.US).

Tom Lee Says Democratic Sweep Could Fuel 15% to 20% Tech Rally
